Can-Fite BioPharma (CANF) Institutional Ownership $2.31 -0.07 (-2.94%) (As of 11:39 AM ET) Add Compare Share Share Today's Range$2.24▼$2.3350-Day Range$1.90▼$2.7052-Week Range$1.52▼$8.74Volume14,659 shsAverage Volume61,671 shsMarket Capitalization$8.18 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Can-Fite BioPharma (NYSE:CANF)CurrentInstitutional OwnershipPercentage1.54%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$755,700.00Number ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$9,501.50 Get CANF Insider Trade Alerts Want to know when executives and insiders are buying or selling Can-Fite BioPharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CANF Institutional Buying and Selling by Quarter Can-Fite BioPharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2023Armistice Capital LLC330,000$0.76M0.0%N/A9.322% 2/15/2023Morgan Stanley304,675$0.19M0.0%-4.8%10.092% 8/13/2022Virtu Financial LLC56,322$52K0.0%N/A0.207% 2/10/2022Acadian Asset Management LLC28,601$36K0.0%-75.1%0.105% 11/16/2021Cetera Advisor Networks LLC130,776$0.22M0.0%-16.9%0.607% 10/15/2021Fifth Third Bancorp30,000$50K0.0%N/A0.149% 8/6/2021StoneX Group Inc.40,000$91K0.0%N/A0.233% 5/21/2021Citadel Advisors LLC60,077$0.15M0.0%N/A0.349% 5/19/2021Virtu Financial LLC46,294$0.11M0.0%-37.5%0.269% 5/18/2021Citadel Advisors LLC60,077$0.15M0.0%N/A0.349% 5/18/2021Jane Street Group LLC10,665$26K0.0%N/A0.062% 5/14/2021XTX Topco Ltd11,205$28K0.0%N/A0.065% 5/14/2021Stifel Financial Corp12,000$30K0.0%N/A0.070% 3/26/2021Susquehanna International Group LLP15,323$27K0.0%N/A0.090% 2/24/2021Virtu Financial LLC74,052$0.13M0.0%+445.7%0.479% 2/10/2021Renaissance Technologies LLC118,894$0.21M0.0%+812.7%0.769% 8/7/2020Virtu Financial LLC31,805$63K0.0%N/A0.206% 2/13/2020Renaissance Technologies LLC32,382$0.11M0.0%N/A2.429% 8/14/2019Morgan Stanley60,981$0.18M0.0%-85.1%4.575% 5/14/2019Taylor Asset Management Inc.538,600$0.47M0.3%-32.4%40.405% 5/13/2019Meitav Dash Investments Ltd.508,630$0.45M0.0%+8.4%2.546% 5/15/2018Anson Funds Management LP1,357,586$1.96M1.5%N/A6.795% 5/15/2018Sabby Management LLC1,228,091$1.77M0.2%N/A6.147% 2/15/2018Meitav Dash Investments Ltd.155,000$0.24M0.0%N/A0.935% (Data available from 1/1/2016 forward) CANF Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CANF shares? During the previous two years, the following institutional investors and hedge funds held shares of Can-Fite BioPharma shares: Armistice Capital LLC ($0.76M), Morgan Stanley ($0.19M), and Virtu Financial LLC ($52K), Acadian Asset Management LLC ($36K).Learn more on CANF's institutional investors. What percentage of Can-Fite BioPharma stock is owned by institutional investors? 1.54% of Can-Fite BioPharma stock is owned by institutional investors. Learn more on CANF's institutional investor holdings. Which institutional investors have been buying Can-Fite BioPharma stock? The following institutional investors have purchased Can-Fite BioPharma stock in the last 24 months: Armistice Capital LLC ($0.33M), and Virtu Financial LLC ($56.32K). How much institutional buying is happening at Can-Fite BioPharma? Institutional investors have bought a total of 386,322 shares in the last 24 months. This purchase volume represents approximately $1.33M in transactions. Which Can-Fite BioPharma major shareholders have been selling company stock? The following institutional investors have sold Can-Fite BioPharma stock in the last 24 months: Acadian Asset Management LLC ($86.21K), and Morgan Stanley ($15.50K). How much institutional selling is happening at Can-Fite BioPharma? Institutional investors have sold a total of 101,706 shares in the last 24 months. This volume of shares sold represents approximately $1.12M in transactions. Related Companies: Applied Molecular Transport Major Shareholders Guardion Health Sciences Major Shareholders Sunshine Biopharma Major Shareholders Lixte Biotechnology Major Shareholders Pulmatrix Major Shareholders Lipella Pharmaceuticals Major Shareholders Impel Pharmaceuticals Major Shareholders Bio-Path Major Shareholders Flora Growth Major Shareholders Pasithea Therapeutics Major Shareholders This page (NYSE:CANF) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.